Compare Charles Schwab Corporation Common Stock (SCHW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs Viatris Inc — how do they compare? Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 8.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 85 Days and Viatris Inc for 57 Days on average.
| SCHW | VTRS | |
|---|---|---|
Market Cap | $167.52B | $20.03B |
Volume | 6,554,126 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $113.65 | $18.27 |
52-Week Low | $85.35 | $9.74 |
Typical Hold Time | 85 Days | 57 Days |
Enterprise Value | $153.97B | $32.15B |
Dividend Yield | 1.32% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $96.87, up 1.35% on the day, with a bearish technical signal but strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.62 exceeding the $1.56 estimate. Revenue for 2025 reached $23.92 billion, driving a net income margin of 38.79%. Analyst consensus is bullish with a $120.33 price target, and recent news highlights growth in client assets and AI integration for advisors.
The outlook remains positive given strong profitability and market share gains, though technical weakness and interest rate sensitivity pose near-term risks. Earnings momentum and strategic initiatives like the Texas Stock Exchange listing support upside potential, but investors should monitor competitive pressures and macroeconomic volatility.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
